by Barry101 | Aug 18, 2022 | Press Release, Uncategorized
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 — AIM...
by Barry101 | Aug 15, 2022 | Press Release, Uncategorized
OCALA, Fla. – AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases,...
by Barry101 | Aug 15, 2022 | Press Release, Uncategorized
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones –...
by Barry101 | Jul 28, 2022 | Press Release, Uncategorized
Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditionsOCALA, Fla., July 28, 2022 — AIM...
by Barry101 | Jul 20, 2022 | Press Release, Uncategorized
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the...
